Arsenic trioxide in pediatric cancer – a case series and review of literature

Abele, Michael; Müller, Sara-Lena; Schleicher, Sabine; Hartmann, Ulrike; Döring, Michaela; Queudeville, Manon; Lang, Peter; Handgretinger, Rupert; Ebinger, Martin

doi:10.1080/08880018.2021.1872748

Cited by 6 publications

(8 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of all-trans retinoic acid (ATRA) and ATO is effective in treating hematological malignancies. This combination therapy achieved complete remission rates of over 90% and overall survival of up to 99% [23]. Some studies suggested that ATRA combined with ATO can significantly inhibit the proliferation and promote apoptosis of NB4 cells [98].…”

Section: Combined With Molecular-targeted Drugmentioning

confidence: 98%

“…Besides, more recent data suggest that ATO eliminates leukemic stem cells in APL [21]. ATO-induced deactivation of PML-RARα causes malignant promyelocytes to differentiate [22,23]. ATO anti-cancer properties are not limited to only APL.…”

Section: Anti-cancer Mechanismsmentioning

confidence: 99%

“…The anti-angiogenesis effect is the most critical therapeutic potential of ATO, among the recognized mechanisms of its anti-cancer effects [23,40]. Angiogenesis in tumors begins with the breakdown of the extracellular matrix (ECM) induced by matrix metalloproteinase (MMPs).…”

Section: Anti-cancer Mechanismsmentioning

confidence: 99%

“…However, drug resistance is the main challenge for the good prognosis of cancer patients [94]. As a potential new anti-cancer drug, ATO has played a significant role in the combined treatment to reverse/slow down the occurrence of drug resistance [23,93,94,98]. Wang et al showed that ATO combined with dasatinib induced apoptosis more pronouncedly in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) cells.…”

Section: Combined With Molecular-targeted Drugmentioning

confidence: 99%

“…This combinatorial treatment significantly affected the cell-cycle and induced apoptosis [102]. In a clinical trial on recurrent osteosarcoma and Ewing sarcoma, ATO combined with etoposide or paclitaxel achieved complete remission in five of 32 patients and partial response was observed in another six patients [23]. Furthermore, synergistic effects were shown for combining ATO with vincristine, vinblastine and lithium chloride [23].…”

Section: Combined With Chemotherapy Drugsmentioning

confidence: 99%

See 4 more Smart Citations

Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy

Zhang

Fang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Arsenic trioxide (ATO) is one of the first-line chemotherapeutic drugs for acute promyelocytic leukemia. Its anti-cancer activities against various human neoplastic diseases have been extensively studied. However, the clinical use of ATO for solid tumors is limited, and these limitations are because of severe systemic toxicity, low bioavailability, and quick renal elimination before it reaches the target site. Although without much success, several efforts have been made to boost ATO bioavailability toward solid tumors without raising its dose. It has been found that nanomedicines have various advantages for drug delivery, including increased bioavailability, effectiveness, dose-response, targeting capabilities, and safety as compared to traditional drugs. Therefore, nanotechnology to deliver ATO to solid tumors is the main topic of this review, which outlines the previous and present medical applications of ATO. We also summarised ATO anti-cancer mechanisms, limitations, and outcomes of combinatorial treatment with chemo agents. As a result, we strongly recommend conducting pre-clinical and clinical studies of ATO, especially nano-system-based ones that might lead to a novel combination therapy for cancer treatment with high efficacy, bioavailability, and low toxicity for cancer patients.

show abstract

Section: Combined With Molecular-targeted Drugmentioning

confidence: 98%

Section: Anti-cancer Mechanismsmentioning

confidence: 99%

Section: Anti-cancer Mechanismsmentioning

confidence: 99%

Section: Combined With Molecular-targeted Drugmentioning

confidence: 99%

Section: Combined With Chemotherapy Drugsmentioning

confidence: 99%

See 3 more Smart Citations

Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy

Zhang

Fang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date

Yan,

Wang,

Wei

et al. 2023

Arch. Pharm. Res.

View full text Add to dashboard Cite

Arsenic-trioxide

2021

Reactions Weekly

View full text Add to dashboard Cite

Arsenic-trioxide Hyperbilirubinaemia, first-degree atrioventricular block and incomplete right bundle branch block: 3 case reportsIn a retrospective study involving 31 patients who were treated with arsenic trioxide between 2008 and 2018, 3 patients [ages and sexes not stated] were described, who developed hyperbilirubinaemia, first-degree atrioventricular block or incomplete right bundle branch block during treatment with arsenic trioxide for refractory and relapsed cancer [dosages, routes and durations of treatments to reactions onsets not stated].The patients, who had refractory and relapsed cancer, started receiving arsenic trioxide. However, the patients developed grade 3 hyperbilirubinaemia (n=1), a temporary first-degree atrioventricular block (n=1) and a persistent incomplete right bundle branch block (n=1) secondary to the use of arsenic trioxide [not all outcomes stated].

show abstract

Arsenic trioxide in pediatric cancer – a case series and review of literature

Cited by 6 publications

References 85 publications

Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy

Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy

Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date

Arsenic-trioxide

Contact Info

Product

Resources

About